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ABSTRACT 226 
Excessive alcohol consumption is one of the main causes of death and disability 227 
worldwide.  Alcohol consumption is a heritable complex trait.  We conducted a 228 
meta-analysis of genome-wide association studies (GWAS) of gram/day (g/d) alcohol 229 
consumption in UK-Biobank, AlcGen and CHARGE+ consortia accumulating 480,842 230 
people of European descent to decipher the genetic architecture of alcohol intake. 231 
We identified 46 novel, common loci, and investigated their potential functional 232 
significance using magnetic resonance imaging data and gene expression studies. 233 
Our results identify genetic pathways associated with alcohol consumption and 234 
suggest shared genetic mechanisms with neuropsychiatric disorders including 235 
schizophrenia. 236 
  237 
Excessive alcohol consumption is a major public health problem that is responsible 238 
for 2.2% and 6.8% age-standardized deaths for women and men respectively1. Most 239 
genetic studies of alcohol use focus on alcohol dependency, although the population 240 
burden of alcohol-related disease mainly reflects a broader range of alcohol 241 
consumption behaviors2. Small reductions in alcohol consumption could have major 242 
public health benefits; even moderate amounts of alcohol/day may have significant 243 
impact on mortality3. 244 
Alcohol consumption is a heritable complex trait4, but genetic studies to date have 245 
robustly identified only a small number of associated genetic variants 5-8. These 246 
include variants in the aldehyde dehydrogenase (ADH) gene family, a group of 247 
enzymes that catalyze the oxidation of aldehydes9, including a cluster of genes on 248 
chromosome 4q23 (ADH1B, ADH1C, ADH5, ADH6, ADH7)6.  249 
Here, we report a GWAS meta-analysis of alcohol intake (log transformed g/day) 250 
among people of European ancestry drawn from UK Biobank (UKB)10, the Alcohol 251 
Genome-Wide Consortium (AlcGen) and the Cohorts for Heart and Aging Research in 252 
Genomic Epidemiology Plus (CHARGE+) consortia. Briefly, UKB is a prospective 253 
cohort study of ~500,000 individuals recruited between the ages of 40 and 69 years. 254 
Participants were asked to report their average weekly and monthly alcohol 255 
consumption through a self-completed touchscreen questionnaire10. Based on these 256 
reports, we calculated the g/d alcohol intake (Methods). Participants were 257 
genotyped using a customized array with imputation from the Haplotype Reference 258 
Consortium (HRC) panel11, yielding ~7 million common single nucleotide 259 
polymorphisms (SNPs) with minor allele frequency (MAF) ≥ 1% and imputation 260 
quality score [INFO] ≥ 0.1. After quality control (QC) and exclusions (Methods) we 261 
performed GWAS of alcohol consumption using data from 404,731 UKB participants 262 
of European descent under an additive genetic model (Methods and Supplementary 263 
Table 1). We found that genomic inflation in the UKB analysis was λGC=1.45, but did 264 
not adjust for inflation as the LD score regression intercept was 1.05, indicating that 265 
this was due to polygenicity rather than to population stratification12. The estimated 266 
SNP-wide heritability of alcohol consumption in the UKB data was 0.09. 267 
We also carried out GWAS in 25 independent studies from the AlcGen and CHARGE+ 268 
consortia including 76,111 participants of European descent for which alcohol g/d 269 
could be calculated (Supplementary Table 2). Various arrays were used for 270 
genotyping, with imputations performed using either the 1,000 Genomes Reference 271 
Panel or the HRC platforms (Supplementary Table 3). After QC, we applied genomic 272 
control at the individual study level and obtained summary results for ~7 million 273 
SNPs with imputation quality score ≥ 0.3 (Methods).  274 
We combined the UKB, AlcGen and CHARGE+ results using a fixed effects inverse 275 
variance weighted approach for a total of 480,842 individuals13. To maximize power, 276 
we performed a single-stage analysis to test common SNPs with MAF ≥ 1%. We set a 277 
stringent P-value threshold of P < 5 x 10-9 to denote significance in the combined 278 
meta-analysis14, and required signals to be at P < 5 x 10-7 in UKB, with same direction 279 
of effect in UKB and AlcGen plus CHARGE+, to minimize false positive findings. We 280 
excluded SNPs within 500kb of variants reported as genome-wide significant in 281 
previous GWAS of alcohol consumption5,6, identified novel loci by requiring SNPs to 282 
be independent of each other (LD r2 < 0.1), and selected the sentinel SNP within each 283 
locus according to lowest P-value (Methods).  284 
We then tested for correlations of alcohol-associated SNPs with Magnetic Resonance 285 
Imaging (MRI) phenotypes of brain, heart and liver, and gene expression.  We tested 286 
the sentinel SNPs for association with other traits/diseases and Drosophila mutant 287 
models were used to investigate functional effects on ethanol-induced behavior.  288 
RESULTS 289 
Our meta-analysis identified 46 novel loci associated with alcohol consumption (log 290 
transformed g/day) (Fig. 1 and Table 1). All inferential statistics for the novel loci are 291 
reported in Table 1 whereas heterogeneity metrics are presented in Supplementary 292 
Table 4. In addition, we discovered a further eight variants in the combined analysis 293 
at nominal genome-wide significance (P < 1 x 10-8) that may also be associated with 294 
alcohol intake (Supplementary Table 5). The most significantly associated variant, 295 
rs1991556 (P = 4.5 x 10-23), is an intronic variant in MAPT gene that encodes the 296 
microtubule-associated protein tau, and was found through Phenoscanner not only 297 
to be associated with dementia15 and Parkinson’s disease16,17, but also with 298 
neuroticism, schizophrenia18and other traits19-21 (Methods, Fig. 2 and 299 
Supplementary Table 6). The second most significantly associated variant is 300 
rs1004787 (P = 6.7 x 10-17), near SIX3 gene, which encodes a member of the sine 301 
oculis homeobox transcription factor family involved in eye development22. The third 302 
SNP is rs13107325 (P = 1.3 x 10-15), a missense SNP in SLC39A8 303 
(https://www.ncbi.nlm.nih.gov/gene/64116), a gene that encodes a member of the 304 
SLC39 family of metal ion transporters, which has been associated with 305 
schizophrenia23 as well as inflammatory bowel disease, cardiovascular and metabolic 306 
phenotypes 24 25-27 in previous GWAS (Fig. 2 and Supplementary Table 6).  307 
Another of our most significant variants, an intronic SNP rs7121986 (P = 6.2 x 10-14) 308 
in DRD2 (https://www.ncbi.nlm.nih.gov/gene/1813), encodes the dopamine 309 
receptor D2 that has been associated with cocaine addiction, neuroticism and 310 
schizophrenia18. We also found significant associations with SNP rs988748 (P = 4.4 x 311 
10-9) in the BDNF gene (https://www.ncbi.nlm.nih.gov/gene/627, that encodes  a 312 
member of the nerve growth factor family of proteins and rs7517344, which is near 313 
ELAVL4 (https://www.ncbi.nlm.nih.gov/gene/1996) (P = 2.0 x 10-10), the gene 314 
product of which is involved in BDNF regulation28. Previous studies have suggested 315 
that a variant in BDNF is associated with alcohol consumption and that alcohol 316 
consumption modulates BDNF expression29.  317 
 318 
Additionally, we found association of alcohol consumption with SNP rs838145 (P = 319 
3.2 x 10-15), which has been associated with macronutrient intake in a previous 320 
GWAS30. This variant is nearest IZUMO (https://www.ncbi.nlm.nih.gov/gene/284359) 321 
in a locus of around 50kb that spans a number of genes including FGF21 322 
(https://www.ncbi.nlm.nih.gov/gene/26291), whose gene product FGF21 is a liver 323 
hormone involved in the regulation of alcohol preference, glucose and lipid 324 
metabolism31. We previously reported significant association of alcohol intake with 325 
SNP rs11940694 in KLB (https://www.ncbi.nlm.nih.gov/gene/152831), an obligate 326 
receptor of FGF21 in the brain5, and we strongly replicated that finding here (P = 3.3 327 
x 10-68). 328 
 329 
As well as variants in KLB and in the alcohol dehydrogenase locus (smallest P = 1.2 x 330 
10-125), we found support (P = 1 x 10-5) for association of common variants in the 331 
three other alcohol intake-related loci previously reported in GWAS (Supplementary 332 
Table 7), including SNP rs6943555 in AUTS2 333 
(https://www.ncbi.nlm.nih.gov/gene/26053) (P = 2.9 x 10-6). In addition, we found a 334 
novel alcohol intake-related SNP rs1421085 in FTO 335 
(https://www.ncbi.nlm.nih.gov/gene/79068) in high LD (r2 = 0.92) with a variant 336 
reported previously as genome-wide significant for association with alcohol 337 
dependence32. 338 
 339 
Conditional analysis using Genome-wide Complex Trait Analysis (GCTA) did not 340 
reveal any independent secondary signals related to alcohol consumption. Among 341 
~14,000 individuals in the independent Airwave cohort33 (Methods), 7% of the 342 
variance in alcohol consumption was explained by the novel and known common 343 
variants. Using weights from our analysis, we constructed an unbiased weighted 344 
genetic risk score (GRS) in Airwave (Methods) and found a strong association of the 345 
novel and known variants on alcohol consumption levels (P = 2.75 x 10-14), with mean 346 
difference in sex-adjusted alcohol intake of 2.6 g/d comparing the top vs the bottom 347 
quintile of the GRS (Supplementary Table 8).  348 
 349 
Associations with MRI imaging phenotypes 350 
We functionally characterized novel variants by carrying out single-SNP analyses of 351 
the imaging phenotypes in UKB (Methods), focusing on brain (N=9,702), heart 352 
(N=10,706) and liver (N=8,479). 353 
With Bonferroni correction (corrected P-value 6.6 x 10-6, corresponding to 0.05/46 354 
SNPs*164 imaging phenotypes), we found significant positive associations between 355 
SNP rs13107325 in SLC39A8 and the volumes of multiple brain regions; All inferential 356 
statistics for these associations are reported in Supplementary Table 9.  The 357 
strongest associations were with putamen (left: P = 2.5 x 10-45, right: P = 2.8 x 10-47), 358 
ventral striatum (left: P = 9.5 x 10-53, right: P = 9.6 x 10-51) and cerebellum (strongest 359 
association for left I-IV volume; P = 1.2 x 10-9) (Supplementary Table 9); similar 360 
findings were recently reported in a GWAS on brain imaging in UKB34. The other 361 
significant association was for rs1991556 with the parahippocampal gyrus (P = 1.2 x 362 
10-6). 363 
We then tested these brain regions for association with alcohol consumption and 364 
found a significant effect for the left (t8601 = -3.7; beta ± SE = -0.0019 ± 0.0005; P = 365 
2.0 x 10-4) and right (t8601 = -3.65; beta ± SE = -0.0070 ± 0.0005; P = 2.6 x 10-4) 366 
putamen. Finally, we used data from N= 8,610 individuals and performed a 367 
mediation analysis using a standard three-variable path model, bootstrapping 10,000 368 
times to calculate the significance of the mediation effect of putamen volume for 369 
genetic influences on alcohol consumption (Methods). We found evidence that the 370 
effect of SNP rs13107325 in SLC39A8 on alcohol intake is partially mediated via its 371 
association with left (t8601 = -3.03; beta ± SE = -0.27 ± 0.09; P = 1.9 x 10-3) and right 372 
(t8601 = -2.82; beta ± SE = -0.27 ± 0.09; P = 1.7 x 10-3) putamen volume (Fig. 3 and 373 
Supplementary Table 10). To exclude the possibility of an inverse causal pathway we 374 
performed additional analyses in UKB non-drinkers (N =589). With 10,000 random 375 
permutations, associations of rs13107325 with both left and right putamen 376 
remained significant (left putamen: t541=1.06; P = 0.02; right putamen: t541=0.38; P = 377 
0.04) indicating that the association between rs13107325 and putamen regions is 378 
not mediated by alcohol intake.   379 
We did not find any significant associations of novel SNPs with either cardiac (left 380 
ventricular mass or end diastolic volume or right ventricular end diastolic volume) 381 
(Supplementary Table 11) or liver fat measures on MRI (Supplementary Table 12), 382 
after adjustment for multiple testing. 383 
Effects of SNPs on gene expression  384 
We carried out expression quantitative trait loci eQTL analyses using the Genotype-385 
Tissue Expression (GTEx) and the UK Brain Expression Consortium (UKBEC) datasets; 386 
34 of the 53 novel and known SNPs associated with alcohol consumption have a 387 
significant effect on gene expression in at least one tissue, including 33 SNPs that 388 
affect gene expression in the brain (Supplementary Tables 13 and 14, and 389 
Supplementary Figures 1-3). We found that the most significant eQTLs often do not 390 
involve the nearest gene and that several of the SNPs affect expression of different 391 
genes in different tissues. For example, SNP rs1991556 in the MAPT gene 392 
(https://www.ncbi.nlm.nih.gov/gene/4137) affects expression of 33 genes overall, 393 
with most significant effects on the expression of the non-protein coding genes 394 
CRHR1-IT1 (also known as C17orf69 or LINC02210) 395 
(https://www.ncbi.nlm.nih.gov/gene/147081) and LRRC37A4P 396 
(https://www.ncbi.nlm.nih.gov/gene/?term=LRRC37A4P), near MAPT, across a wide 397 
range of tissues including brain, adipose tissue and skin (P = 7.2 x 10-126 to P = 2.5 x 398 
10-6) (Supplementary Figure 2). Similarly, the A-allele at SNP rs2071305 within 399 
MYBPC3 (https://www.ncbi.nlm.nih.gov/gene/4607) affects the expression of 400 
several genes and is most significantly associated with increased expression of 401 
C1QTNF4 (https://www.ncbi.nlm.nih.gov/gene/114900) across several tissues (P = 402 
1.9 x 10-25 to P = 8.4 x 10-5). 403 
Several of these eQTLs were found to affect expression of genes known to be 404 
involved in reward and addiction. SNP rs1053651 in the TCAP-PNMT-STARD3 gene 405 
cluster affects expression of the PPP1R1B gene (also known as DARPP-32) 406 
(https://www.ncbi.nlm.nih.gov/gene/84152) which encodes a protein that mediates 407 
the effects of dopamine in the mesolimbic reward pathway35. Other known 408 
addiction-related genes include 409 
ANKK1 (https://www.ncbi.nlm.nih.gov/gene/255239) and DRD2 (expression affected 410 
by SNP rs7121986) implicated in alcohol and nicotine dependence36,37, CRHR1 411 
(https://www.ncbi.nlm.nih.gov/gene/1394) (affected by SNP rs1991556) involved in 412 
stress-mediated alcohol dependence38,39 and PPM1G (SNP rs1260326) 413 
(https://www.ncbi.nlm.nih.gov/gene/5496) whose epigenetic modification was 414 
reported to be associated with alcohol abuse40. 415 
Over-representation enrichment analyses based on functional annotations and 416 
disease-related terms indicated that genes whose expressions are affected by the 417 
identified eQTLs are most significantly enriched for terms related to abdominal 418 
(n=91) and other malignant cancers, motor function (n= 5) and cellular homeostasis 419 
(n= 22) (Supplementary Figure 4). We performed a gene-based analysis and 420 
repeated the over-representation enrichment analysis adding the new set of 421 
identified genes (Supplementary Table 15). The results were similar supporting an 422 
enrichment for abdominal (n=100) and other cancers, as well as motor function 423 
(n=5) and cellular homeostasis (n=24) (Supplementary Figure 5).   424 
Other traits and diseases 425 
 426 
Using LD score regression12, we assessed genetic correlations between alcohol 427 
consumption and 235 complex traits and diseases from publicly available summary 428 
GWAS statistics (Methods).  All results including their statistics (i.e. rg, standard 429 
errors, z value and P value) are included in Supplementary Table 16. The strongest 430 
positive genetic correlations based on false discovery rate P < 0.02 were found for 431 
smoking (rg= 0.42, P = 1.0 x 10-23) and HDL cholesterol levels (rg= 0.26, P = 5.1 x 10-13). 432 
We also found negative correlations for sleep duration (rg= -0.14, P = 3.8 x 10-7) and 433 
fasting insulin levels (rg= -0.25, P = 4.5 x 10-6). A significant genetic correlation was 434 
also found with schizophrenia (rg= 0.07, P = 3.9 x 10-3) and bipolar disorder (rg= 0.15, 435 
P = 5.0 x 10-4) (Supplementary Table 16). Over-representation enrichment analysis 436 
using WebGestalt41 (http://www.webgestalt.org) showed that our list of novel and 437 
known variants is significantly enriched for several diseases and traits including 438 
developmental disorder in children (P = 7.3 x 10-5), epilepsy (P = 1.4 x 10-4), heroin 439 
dependence (P = 5.7 x10-4) and schizophrenia (P = 8.4 x 10-4) (Supplementary Figure 440 
6). The result of the Mendelian randomization analysis (Methods) to assess a 441 
potential causal effect of alcohol on schizophrenia risk, using the inverse variance 442 
weighted approach, was not significant (P = 0.089), with large heterogeneity of the 443 
estimates of the tested variants. 444 
Functional studies in Drosophila 445 
Based on our GWAS and brain imaging findings we took forward SNP rs13107325 in 446 
SLC39A8 (alias Zip8 gene) for additional testing in Drosophila, which employ 447 
conserved mechanisms to modulate ethanol-induced behaviors42,43. First, we 448 
overexpressed human Zip8 using a Gal4-driver that included expression in neurons 449 
involved in multiple ethanol-induced behaviors43. Flies carrying icsGal4/+ UAS-450 
hZip8/+ showed a slight, but significant, resistance to ethanol-induced sedation 451 
compared to control flies (t30 = 2.3; Hedge’s g = 0.80; 95% CI: 0.08 – 1.53; P = 0.026; 452 
N = 16 per genotype). Ethanol tolerance, induced with repeat exposures spaced by a 453 
4-hour recovery, was unchanged in these flies (t = 1.0; P = 0.33; Fig. 4a). We next 454 
used the same Gal4-driver to knock down the endogenous Drosophila ortholog 455 
of hZip8, namely dZip71B. This caused the flies to display naïve sensitivity to ethanol-456 
induced sedation (t14 = 3.98; Hedge’s g = -1.84; 95% CI: -0.67 – -3.01; P = 0.0014; N = 457 
8 per genotype), and in addition, these flies developed greater tolerance to ethanol 458 
upon repeat exposure (t14 = 4.80; Hedge’s g = 2.29; 95% CI: 1.03 – 3.55; P = 0.0003; 459 
Fig. 4b). To corroborate this phenotype, we then tested flies transheterozygous for 460 
two independent transposon-insertions in the middle of the dZip71B gene 461 
(Supplementary Figure 7) and found that these dZip71BMi / MB flies also displayed 462 
naïve sensitivity (t14 = 3.23; Hedge’s g = -1.54; 95% CI: -0.42 – -2.65; P = 0.006) and 463 
increased ethanol-induced tolerance (t14 = 2.39; Hedge’s g = 1.13; 95% CI: 0.07 - 464 
2.18; P = 0.032) compared to controls (N = 8 each) (Fig. 4c). 465 
 466 
DISCUSSION 467 
Our discovery utilizing data on common variants from over 480,000 people of 468 
European descent extends our knowledge of the genetic architecture of alcohol 469 
intake, increasing the number of identified loci to 46.  We found loci involved in 470 
neuropsychiatric conditions such as schizophrenia, Parkinson’s disease and 471 
dementia, as well as BDNF where gene expression is affected by alcohol abuse. Our 472 
findings illustrate that large-scale studies of genetic associations with alcohol intake 473 
in the general population, rather than on alcohol dependency alone, can provide 474 
additional insights into genetic mechanisms regulating alcohol consumption. 475 
We highlight the role of the highly pleiotropic MAPT and SLC39A8 genes in the 476 
genetics of alcohol consumption. MAPT plays a key role in tau-associated dementia44 477 
and both genes are also implicated in other neuropsychiatric conditions including 478 
neuroticism, schizophrenia and Parkinson’s disease16-18. The SLC39A8 gene encodes a 479 
member of the SLC39 family of metal ion transporters. The encoded protein is 480 
glycosylated and found in plasma membrane and mitochondria, and is involved in 481 
the cellular transport of zinc, modulation of which could affect microglial 482 
inflammatory responses45. Our gain- and loss-of-function studies in Drosophila 483 
indicate a potential causal role of SLC39A8 in alcohol drinking behavior, even though 484 
results should be interpreted with caution due to small sample size in our 485 
experiment. The MRI brain imaging demonstrates a significant association of SNP 486 
rs13107325 in the SLC39A8 gene and putamen volume differences, and these 487 
structural differences appear to partially mediate associations of rs13107325 with 488 
alcohol consumption.  The putamen has been associated with alcohol consumption 489 
and the withdrawal syndrome after chronic administration to rodents and non-490 
human primates46. Our mediation analysis is suggestive of a plausible causal pathway 491 
linking rs13107325 in SLC39A8 with alcohol intake via an effect on putamen volume, 492 
but follow-up work is needed to conclusively demonstrate causal links. Putamen 493 
volume differences have also been associated with both schizophrenia and 494 
psychosis47,48 and robust association between SNP rs13107325 in SLC39A8 and 495 
schizophrenia was reported in a previous GWAS23.  496 
We also report SNP rs7121986 near DRD2 as a novel alcohol intake variant in GWAS. 497 
The gene product of DRD2, D2 dopamine receptor, is a G protein-coupled receptor 498 
on post-synaptic dopaminergic neurons that has long been implicated in 499 
alcoholism49. In addition, we identify SNP rs988748 in BDNF as a novel alcohol intake 500 
variant; BDNF expression is differentially affected by alcohol exposure in animal 501 
models50,51. Both genes (along with PPP1R1P) are centrally involved in reward-502 
mediating mesocortico-limbic pathways and both are implicated in the development 503 
of schizophrenia. For example, there is a robust GWAS association between 504 
schizophrenia and SNP rs4938021 in DRD2 (in perfect LD with our novel alcohol 505 
intake-related variant rs7121986) and DRD2 appears to be pivotal in network 506 
analyses of genes involved in schizophrenia52.  Taken together, our results suggest 507 
that there are shared genetic mechanisms between the regulation of alcohol intake 508 
and susceptibility to schizophrenia, as well as other neuropsychiatric disorders. In 509 
this regard, large prospective epidemiological studies report a three-fold risk of 510 
schizophrenia in relation to alcohol abuse53.  511 
We previously reported genome-wide significant associations of alcohol intake with 512 
KLB, and identified a liver-brain axis linking the liver hormone FGF21 with central 513 
regulation of alcohol intake involving β-Klotho receptor (the gene product of KLB) in 514 
the brain5. Here, we identify a significant variant near FGF21 gene and strongly 515 
replicate the previously reported KLB gene variant, strengthening the genetic 516 
evidence for the importance of this pathway in regulating alcohol consumption.  517 
The LD score regression analysis showed a positive genetic correlation between 518 
alcohol consumption, smoking and HDL cholesterol levels. This confirms previous 519 
findings that reported an almost identical genetic correlation of alcohol consumption 520 
with number of cigarettes per day54. Furthermore, the observed genetic correlation 521 
with HDL levels is consistent with previous observations of an association between 522 
alcohol consumption and HDL55,56, including results of a Mendelian randomization 523 
study that suggested a possible causal role linking alcohol intake with increased HDL 524 
levels57.  Furthermore, we found a genetic correlation (inverse) between sleep 525 
duration and alcohol consumption, an association previously reported only in a few 526 
small epidemiological studies58. We also found a significant genetic correlation with 527 
schizophrenia and bipolar disorder, a result that is supported by a recently published 528 
trans-ethnic meta-analysis of case-control studies on alcohol dependence59. We 529 
could not test for a genetic association between alcohol and risk of alcohol-related 530 
cancers60 because of limited availability of summary data. However, our gene-set 531 
enrichment analysis showed a significant enrichment for genes related to abdominal 532 
as well as other cancers.   533 
Strengths of our study include its size, detailed attention to the alcohol phenotype, 534 
dense coverage of the genome through imputation, and incorporation of brain and 535 
other imaging data to explore potential mechanisms. Over 80% of the data came 536 
from UKB, which combines high-quality phenotypic data and imputed genome-wide 537 
genetic data with strict attention to quality control61. We adopted a stringent 538 
approach to claim novel variants involving a conservative P-value threshold, internal 539 
replication in UKB and consistent direction of effect with the other studies, to 540 
minimize the reporting of false positive signals. 541 
However, since alcohol intake is socio-culturally as well as genetically determined, it 542 
is influenced by other lifestyle and environmental factors which may modify or dilute 543 
the genetic signal. A key limitation is that assessment of alcohol intake relies on self-544 
report, which is prone to errors and biases including recall bias and systematic 545 
under-reporting by heavy drinkers62,63. Furthermore, questionnaires on alcohol 546 
intake covered a short duration (e.g. day or week) at a single period, which may not 547 
be representative of broader drinking patterns of cohort participants. We 548 
harmonized data across cohorts by converting alcohol intake into a common metric 549 
of g/d, with imputation as necessary in UKB for participants reporting consumption 550 
of small amounts of alcohol. Taking this approach, we were able to detect strong 551 
genetic associations with alcohol intake that explained 7% of the variance in alcohol 552 
in an independent cohort, while our GRS analysis indicates that individuals in the 553 
lower fifth of the GRS distribution were consuming daily approximately one third of a 554 
standard drink (2.6 g/d alcohol) less compared with those in the upper fifth.   555 
We should also point out that our eQTL analyses are a first step in the identification 556 
of causal genes. Yet, as the most significant eQTLs affected expression of many 557 
genes, not necessarily the nearest, there is a need to further prioritize potential 558 
causal genes. Unbiased strategies that leverage information from multiple data sets 559 
including extensive genomic annotations and high-throughput functional screening 560 
in a broad range of tissues will be essential for effective prioritization of genes and 561 
uncovering of underlying causal mechanisms64. Establishing confidence in the 562 
prioritized genes in such a way is a prerequisite for performing functional follow-up 563 
studies in appropriate model systems, as demonstrated by the identification of the 564 
causal genes and potential disease mechanisms at the obesity- associated FTO 565 
locus65. 566 
 567 
In summary, in this large study of genetic associations with alcohol consumption, we 568 
identified common variants in 46 novel loci, with several of the genes expressed in 569 
the brain as well as other tissues. Our findings suggest that there may be shared 570 
genetic mechanisms underpinning regulation of alcohol intake and development of a 571 
neuropsychiatric disorders including schizophrenia. This may form the basis for 572 
greater understanding of observed associations between alcohol consumption, 573 
schizophrenia66 and other disorders. 574 
METHODS 575 
 576 
UK Biobank data 577 
We conducted a Genome Wide Association Study (GWAS) analysis among 458,577 578 
UKB participants of European descent, identified from a combination of self-579 
reported and genetic data. The details of the selection of the participants has been 580 
described elsewhere14. These comprise 408,951 individuals from UKB genotyped at 581 
825,927 variants with a custom Affymetrix UK Biobank Axiom Array chip and 49,626 582 
individuals genotyped at 807,411 variants with a custom Affymetrix UK BiLEVE Axiom 583 
Array chip from the UK BiLEVE study, which is a subset of UKB. For our analyses, we 584 
used SNPs imputed centrally by UKB using the Haplotype Reference Consortium 585 
(HRC) panel.  586 
 587 
Alcohol intake  588 
We calculated the alcohol intake as grams of alcohol per day (g/d) based on self-589 
reported alcohol drinking from the touch-screen questionnaire. The quantity of each 590 
type of drink (red wine, white wine, beer/cider, fortified wine, spirits) was multiplied 591 
by its standard drink size and reference alcohol content. Drink-specific intake during 592 
the reported drinking period (a week for frequent drinkers defined as: daily or 593 
almost daily/once or twice a week/three or four times a week; or a month for 594 
occasional drinkers defined as: one to three times a month/special occasions only) 595 
was summed up and converted to g/d alcohol intake for all participants with 596 
complete response to the quantitative drinking questions. The alcohol intake for 597 
participants with incomplete response was imputed by bootstrap resampling from 598 
the complete responses, stratified by drinking frequency (occasional or frequent) 599 
and sex.   600 
 601 
Participants were defined as life-time non-drinkers if they reported ‘never’ on the 602 
question on alcohol drinking frequency (UKB field 1558) and ‘no’ for the question on 603 
former drinker (UKB field 3731); they were excluded from further analysis. We 604 
considered participants with alcohol consumption > 500 g/d as outliers and they 605 
were dropped from the analyses. We also excluded participants with missing 606 
covariates, leaving data on 404,732 individuals.  We log10 transformed g/d alcohol 607 
and sex-specific residuals were derived from the regression of log10 transformed g/d 608 
alcohol on age, age2, genotyping chip and weight.  609 
 610 
UKB genetic analysis  611 
We performed linear mixed modeling using BOLT-LMM software67, under an additive 612 
genetic model, for associations of measured and imputed SNPs with alcohol 613 
consumption (sex-specific residuals of the log10 transformed g/d variable). Model 614 
building was based on SNPs with MAF > 5%, call rate > 98.5% and HWE P > 1 x 10-6. 615 
SNPs were imputed using the HRC panel with imputation quality INFO score > 0.1. 616 
We estimated the LD score regression (LDSR) intercept to assess the degree of 617 
genomic inflation beyond polygenicity as well as the lambda inflation factor λGC68.  618 
The Alcohol Genome-Wide Consortium (AlcGen) and the Cohorts for Heart and 619 
Aging Research in Genomic Epidemiology Plus (CHARGE+) consortia  620 
We analyzed available GWAS data from 25 independent studies (N=76,111) from the 621 
AlcGen and the CHARGE+ consortia. All study participants were of reported 622 
European ancestry and data were imputed to either the 1000 Genome Project or the 623 
HRC panel. Alcohol intake in g/d was computed and the log10 transformed residuals 624 
were analyzed as described above. Study names, cohort information and general 625 
study methods are included in Supplementary Table 2 and 3. 626 
All studies were centrally quality-controlled using easyQC69 including filtering for 627 
MAF. Finally, we analyzed data on ~7.1 M SNPs at MAF >1% and imputation quality 628 
score (Impute [Info score] or Mach [r2]) > 0.3. Genomic control (GC) was applied at 629 
study level. We synthesized the available GWAS using a fixed effects inverse variance 630 
weighted meta-analysis and summary estimates were derived for AlcGen and 631 
CHARGE+.  632 
One-stage meta-analysis 633 
We performed a one-stage meta-analysis applying a fixed-effects inverse variance 634 
weighted meta-analysis using METAL70 to obtain summary results from the UKB and 635 
and the AlcGen plus CHARGE+ GWAS, for up to N=480,842 participants and ~7.1 M 636 
SNPs with MAF ≥ 1% for variants present in both the UKB data and AlcGen and 637 
CHARGE+ meta-analysis. We assessed the observed heterogeneity using Cochran’s Q 638 
and we quantified this using the I2 metric. We considered a Cochran’s Q  P < 1 × 10-4 639 
as significant. The LDSR intercept (standard error), in the discovery meta-analysis 640 
was 1.05 and no further correction was applied. QQ plots of the combined meta-641 
analysis summary results , UK Biobank only as well as AlcGen and CHARGE+ only, are 642 
presented in Supplementary Figure 8.  643 
 644 
Previously reported (known) SNPs 645 
We looked up in the GWAS catalog (http://www.ebi.ac.uk/gwas/) and identified 17 646 
SNPs associated with alcohol consumption at genome-wide significance level (P < 5 647 
× 10-8). We enhanced the list by reference to a recent GWAS by Clarke et al6 that 648 
was not covered by the GWAS catalog at the time of the analysis, reporting 14 649 
additional rare and common SNPs. Together with a SNP in RASGRF2 shown to be 650 
associated with alcohol-induced reinforcement71, we found 31 previously reported 651 
alcohol consumption related SNPs.  652 
 653 
Novel loci 654 
According to locus definition of i) SNPs within ±500kb distance of each other; ii) SNPs 655 
in linkage disequilibrium LD (r2 > 0.1) calculated with PLINK, we augmented the list of 656 
known SNPs with all SNPs present within our data, not contained within the 657 
previously published loci. We further excluded SNPs in the HLA region (chromosome 658 
6, 25-34Mb) due to its complex LD structure. We performed LD clumping in PLINK on 659 
4,515 unknown SNPs with P < 1 10-8 using an r2 > 0.1 and distance threshold of 660 
500kb. We further grouped the lead SNPs within 500kb from each other into the 661 
same loci and selected the SNP with smallest P-value from the locus as sentinel SNP.  662 
To report a SNP as novel signal of association with alcohol consumption: 663 
×
i) the sentinel SNP has P < 5 × 10-9 in the one-stage meta-analysis;  664 
ii) the sentinel SNP is strongly associated (P < 5 × 10-7) in the UKB GWAS 665 
alone; 666 
iii) the sentinel SNP has concordant direction of effect between UKB and 667 
AlcGen and CHARGE+ datasets; 668 
iv) The sentinel SNP is not located within any of the previously reported loci 669 
We selected the above criteria i) to iii) to minimize false positive findings including 670 
use of a conservative one-stage P-value threshold that is an order of magnitude 671 
more stringent than a genome-wide significance P-value. (The threshold of P < 5 × 672 
10-9 has been proposed e.g. for whole-genome sequencing-based studies.) This 673 
approach led us to the identification of 46 sentinel SNPs in total. Regional plots for 674 
all 46 sentinel SNPs are presented in Supplementary Figure 9. 675 
 676 
Conditional analysis 677 
We conducted locus-specific conditional analysis using the GCTA (Genome-wide 678 
Complex Trait Analysis) software (http://cnsgenomics.com/software/gcta). For each 679 
of the 46 novel sentinel SNPs, we obtained conditional analysis results for the SNPs 680 
with MAF>1% and within 500kb from the sentinel SNP after conditioning on the 681 
sentinel SNP. The meta-analysis results of the GWAS in UKB, AlcGen and CHARGE+ 682 
were used as input summary statistics and the individual-level genetic data from UKB 683 
were used as the reference sample. Results for a SNP were considered conditionally 684 
significant if the difference between the conditional P-value and the original P-value 685 
is greater than 1.5-fold (-log10P/-log10(P_conditional) >1.5) and the conditional P-686 
value is smaller than 5 × 10-8.  687 
 688 
Gene-based analysis  689 
We performed a gene-based analysis using fastBAT, a method that performs a set-690 
based association analysis using summary-level data from GWAS. We used the UKB 691 
dataset as a reference set for the LD calculation72. Gene-based associations with P < 692 
5 × 10-9 were considered significant.   693 
 694 
Gene expression analyses 695 
To analyze the impact of genetic variants on expression of neighboring genes and 696 
identify expression quantitative trait loci (cis-eQTLs; i.e., SNPs associated with 697 
differences in local gene expression), we used two publicly available databases, the 698 
Genotype-Tissue Expression (GTEx) database73 (www.gtexportal.org) and the UK 699 
Brain Expression Consortium (UKBEC) dataset74 (http://www.braineac.org). We 700 
searched these databases for significant variant-transcripts pairs for genes within 701 
1Mb of each input SNP. 702 
With the GTEx database, we tested for cis-eQTL effects in 48 tissues from 620 703 
donors. The data described herein were obtained from the GTEx Portal, Release: V7 704 
and used FastQTL75, to map SNPs to gene-level expression data and calculate q-705 
values based on beta distribution-adjusted empirical P-values76. A false discovery 706 
rate (FDR) threshold of ≤0.05 was applied to identify genes with a significant eQTL. 707 
The effect size, defined as the slope of the linear regression, was computed in a 708 
normalized space (normalized effect size (NES)), where magnitude has no direct 709 
biological interpretation. Here, NES reflects the effects of our GWAS A1 alleles (that 710 
are not necessarily the alternative alleles relative to the reference alleles, as 711 
reported in the GTEx database). Supplementary Table 13 lists transcripts-SNPs 712 
associations with significant eQTL effects. 713 
With the UKBEC dataset that comprises 134 brains (http://www.braineac.org/), we 714 
searched for cis-eQTLs in 10 brain regions, including the cerebellar cortex (CRBL), 715 
frontal cortex (FCTX), hippocampus (HIPP), medulla (specifically inferior olivary 716 
nucleus, MEDU), occipital cortex (specifically primary visual cortex, OCTX), putamen 717 
(PUTM), substantia nigra (SNIG), thalamus (THAL), temporal cortex (TCTX) and 718 
intralobular white matter (WHMT), as well as across all brain tissues (aveALL). 719 
MatrixEQTL77 generated P-values for each expression profile (either exon-level or 720 
gene-level) against the respective SNP were obtained for the 10 different tissues and 721 
overall (aveALL). Supplementary Table 14 lists transcripts-SNPs associations with a 722 
eQTL P-value < 0.0045 in at least one brain tissue. Subsequent data analysis was 723 
performed in R (http://www.R-project.org/). 724 
We carried out over-representation enrichment analysis using a list of 146 GTEx 725 
eQTL genes that were derived from the single-variant analysis and a list of 160 eQTL 726 
genes that were derived from both single-variant and gene-based analysis. Ingenuity 727 
pathway analysis (IPA®, QIAGEN Inc.) was performed on these lists using ontology 728 
annotations from all available databases except those derived from low-confidence 729 
computational predictions.  730 
Magnetic Resonance Imaging Data 731 
We used the most recent release of magnetic resonance imaging (MRI) data on 732 
brain, heart and liver for UKB participants to investigate genetic associations with the 733 
46 novel SNPs for alcohol consumption.   734 
 735 
Brain imaging  736 
 737 
Brain MRI acquisition and pre-processing 738 
We used the T1 data from UKB to elucidate volumetric brain structures, including the 739 
cortical and the sub-cortical areas. The T1 data were acquired and pre-processed 740 
centrally by UKB. The brain regions were defined by combining the Harvard-Oxford 741 
cortical and subcortical atlases78 (https://fsl.fmrib.ox.ac.uk/fsl/fslwiki/Atlases) and 742 
the Diedrichsen cerebellar atlas79 743 
(http://www.diedrichsenlab.org/imaging/propatlas.htm). FAST (FMRIB’s Automated 744 
Segmentation Tool)80 was then used to estimate the grey matter partial volume 745 
within each brain region. Subcortical region volumes were also modelled by using 746 
FIRST (FMRIB’s Integrated Registration and Segmentation Tool). More details about 747 
the MRI scanning protocol and pre-processing has been provided in UKB 748 
documentation (https://biobank.ctsu.ox.ac.uk/crystal/docs/brain_mri.pdf). 749 
Association Analyses 750 
We performed association analyses on N = 9,702 individuals between all novel SNPs 751 
and the grey matter volume of brain regions using Pearson correlation, adjusting for 752 
age, age2, sex, age × sex, age2 × sex, and head size. All, brain volume features, log 753 
transformed alcohol intake data (g/d), and the confounders were firstly transformed 754 
by using a rank-based inverse Gaussian transformation. Significance levels were set 755 
at P < 0.05 adjusted using the false-discovery rate method for multiple comparisons.  756 
 757 
Mediation analysis 758 
To assess if the effect of a SNP on alcohol consumption is mediated through a brain 759 
region, we performed a single-level mediation analysis based on a standard three-760 
variable path model (SNP-brain region-alcohol consumption) with corrected and 761 
accelerated percentile bootstrapping 10,000 times to calculate the significance of 762 
the mediation effect. We considered as mediator variable the grey matter volume of 763 
brain regions that had a significant association on alcohol consumption. We 764 
calculated the significance of path a, path b and a*b mediation (SNP-brain region-765 
alcohol consumption) using a multilevel mediation and moderation (M3) toolbox81,82. 766 
To exclude the possibility of an inverse causal pathway we performed additional 767 
analyses in UKB non-drinkers (N =589). performing 10,000 random permutations, 768 
associations of rs13107325 with both left and right putamen. 769 
 770 
Cardiac Imaging  771 
 772 
Cardiac MRI acquisition and pre-processing 773 
Details of the cardiac image acquisition in UKB are reported previously83. Cardiac 774 
MRI was acquired using a clinical wide bore 1.5T scanner (MAGNETOM Aera, Syngo 775 
Platform VD13A, Siemens Healthcare, Erlangen, Germany) with 48 receiver channels, 776 
a 45 mT/m and 200 T/m/s gradient system, an 18-channel anterior body surface coil 777 
used in combination with 12 elements of an integrated 32 element spine coil and 778 
electrocardiogram gating for cardiac synchronization. A two-dimensional short-axis 779 
cardiac MRI was obtained using a balanced steady state free precession to cover the 780 
entire left and right ventricle (echo time, 1.10msec; repetition time, 2.6msec; flip 781 
angle, 80°; slice thickness, 8mm with 2mm gap; typical field of view, 380×252mm; 782 
matrix size, 208×187, acquisition of 1 slice per breath-hold). 783 
The cardiac images were segmented to provide left ventricular mass (LVM), left end-784 
diastolic (LVEDV), left end-systolic volume (LVESV), and right end-diastolic (RVEDV) 785 
and right end-systolic volume (RVESV) using a fully convolutional network as 786 
described previously84. Left (LVEF) and right ventricular ejection fraction (RVEF) were 787 
derived from (LVEDV–LVESV)/LVEDV×100 and (RVEDV–RVESV)/RVEDV×100, 788 
respectively. 789 
Association Analyses 790 
To test associations between cardiac MRI measures and alcohol consumption-791 
related SNPs, we carried out a regression of LVM, LVEDV, LVEF, RVEDV, and RVEF 792 
onto each of the 46 SNPs adjusting for age, sex, height, weight, hypertension 793 
(defined as systolic blood pressure >140mmHg and or diastolic blood pressure 794 
>90mmHg or under antihypertensive treatment), diabetes, and smoking history on 795 
N=10,706 participants.  Significance levels were set at P < 0.05 adjusted using the 796 
false-discovery rate method for multiple comparisons.  797 
 798 
Liver Imaging  799 
Liver MRI acquisition and pre-processing 800 
Details of the liver image acquisition protocol have been reported previously85. 801 
Briefly, all participants were scanned in a Siemens MAGNETOM Aera 1.5-T MRI 802 
scanner (Siemens Healthineers, Erlangen, Germany) using a 6-minute dual-echo 803 
Dixon Vibe protocol, providing a water and fat separated volumetric data set for fat 804 
and muscle covering neck to knees. For liver proton density fat fraction (PDFF) 805 
quantification, an additional single multi-echo gradient slice was acquired over the 806 
liver. Liver images were analysed by computing specific ROI for water, fat and T2* by 807 
magnitude-based chemical shift technique with a 6-peak lipid model, correcting for 808 
T1 and T2*. 809 
 810 
Association Analyses 811 
 812 
We performed association analyses between 46 alcohol consumption-related SNPs 813 
and liver PDFF (%), from 8,479 samples, using a linear regression model adjusting for 814 
age, age2, sex, T2D, BMI, genotyping chip and first three PCs. Liver PDDF was firstly 815 
transformed by using a rank-based inverse transformation. Significance levels were 816 
set at P < 0.05 adjusted using the false-discovery rate method for multiple 817 
comparisons.  818 
 819 
Drosophila experiments 820 
Flies were kept on standard cornmeal/molasses fly food in a 12:12hr light:dark cycle 821 
at 25°C.  Transgenc flies were obtained from the Bloomington Drosophila Stock 822 
Center: UAS-hZip8 BL#66125, UAS-dZIP71B-TRiP-RNAiHMC04064 BL#55376, 823 
dZip71BMI13940 BL#59234, and dZip71BMB11703 BL#29928.  For behavioral experiments, 824 
crosses were set up such that experimental and control flies were sibling progeny 825 
from a cross, and both were therefore in the same hybrid genetic background (w 826 
Berlin / unknown).  Flies aged 1-5 days of adult age were collected, exposed to 827 
100/50 (flowrates) ethanol/air vapor in the Booze-o-Mat 2 days later, and their loss 828 
of righting determined by slight tapping, as described86.  For tolerance, flies were put 829 
back onto regular food after a 30-min initial exposure and were then re-exposed to 830 
the same vapor 4 hours later.  Note that tolerance is not connected to initial 831 
sensitivity, and flies naively sensitive to ethanol-induced sedation can have no, or a 832 
reduced tolerance phenotype. Flies overexpressing hZip8 (and their sibling controls) 833 
were placed at 28°C for two days to increase the expression levels of the transgene, 834 
as we did not detect a phenotype when they were kept at 25°C (data not shown).  835 
Data from experimental and control flies were compared by two-sided Student’s t-836 
tests. Data were normally distributed according to Shapiro-Wilk testing with 837 
Bonferroni adjustment for each of the three experiments.  838 
 839 
Effects on other traits and diseases 840 
We queried SNPs against GWAS results included in PhenoScanner 841 
(http://www.phenoscanner.medschl.cam.ac.uk), to investigate cross-trait effects, 842 
extracting all association results with genome-wide significance at P < 5 × 10-8 for all 843 
SNPs in high LD (r2 ≥ 0.8) with the 46 sentinel novel SNPs, to highlight the loci with 844 
strongest evidence of association with other traits. At the gene level, 845 
overrepresentation enrichment analysis (ORA) with WebGestalt41 on the nearest 846 
genes to all alcohol consumption loci was carried out.  847 
The genetic correlations between alcohol consumption and 235 other traits and 848 
diseases were obtained in the online software LD Hub. LD hub is a centralized 849 
database of summary-level GWAS results and a web interface for LD score regression 850 
analysis  851 
To estimate the potential causal effect of alcohol consumption-related variants on 852 
schizophrenia, we performed a Mendelian randomization analysis utilizing publicly 853 
available GWAS data on schizophrenia and the Mendelian randomization package in 854 
R. The effect was estimated using the inverse-variance weighted (IVM) method. 855 
Pleiotropy was tested by applying the MR-Egger regression method and 856 
heterogeneity statistics were obtained. In presence of heterogeneity the random 857 
effects inverse-variance method was applied87.  858 
Genetic risk scores and percentage of variance explained 859 
We calculated an unbiased weighted GRS in 14,004 unrelated participants in 860 
Airwave, an independent cohort with high quality HRC imputed genetic data33. All 861 
previously reported and novel variants were used for the construction of the GRS. 862 
We weighted the alcohol-increasing alleles by the beta coefficients of the meta-863 
analysis. We assessed the association of the GRS with alcohol intake and calculated 864 
the alcohol consumption levels for individuals in the top vs the bottom quintiles of 865 
the distribution. To calculate the percent of variance of alcohol consumption 866 
explained by genetic variants, we generated the residuals from a regression of 867 
alcohol consumption in Airwave. We then fit a second linear model for the trait 868 
residuals with all novel and known variants plus the top 10 principal components and 869 
estimated the percentage variance of the dependent variable explained by the 870 
variants.  871 
Statistical analysis 872 
All inferential statistics for the analyses described above are provided in the text or 873 
in tables and figures. All performed tests were two-sided.  874 
Data availability statement 875 
The UKB GWAS data can be assessed from the UK Biobank data repository 876 
(http://biota.osc.ox.ac.uk/). The genetic and phenotypic UKB data are available upon 877 
application to the UK Biobank (https://www.ukbiobank.ac.uk). Summary GWAS data 878 
data can be assessed by request to the corresponding authors and will be available 879 
via LDHub (http://ldsc.broadinstitute.org/ldhub/). 880 
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Table 1:  Association results of 46 novel alcohol variants identified through the meta-analysis of UK Biobank and AlcGen and CHARGE+. Results are ordered 
by P-value of combined analysis. 
leadSNP Combined UKB AlcGen and CHARGE+ 
Nearest_Gene Annotated Gene 
rsID_LEAD_S
NP CP EA EAF BETA SE P BETA SE P BETA SE P 
MAPT STH rs1991556 17:44083402 A 0.22 -0.012 0.001 4.5E-23 -0.013 0.001 2.4E-21 -0.011 0.004 4.0E-03 
RP11-89K21.1 SIX3 rs1004787 2:45159091 A 0.54 0.009 0.001 6.7E-17 0.009 0.001 1.1E-15 0.007 0.003 1.4E-02 
SLC39A8 SLC39A8 rs13107325 4:103188709 T 0.07 -0.016 0.002 1.3E-15 -0.017 0.002 4.8E-16 -0.006 0.006 3.6E-01 
IZUMO1, RASIP1, FUT1 IZUMO1 rs838145 19:49248730 A 0.55 -0.008 0.001 3.2E-15 -0.009 0.001 2.4E-15 -0.004 0.003 1.7E-01 
na PSMD7 rs1104608 16:73912588 C 0.43 -0.008 0.001 1.2E-14 -0.009 0.001 4.9E-15 -0.003 0.003 2.5E-01 
MYBPC3 MYBPC3 rs2071305 11:47370957 A 0.69 0.009 0.001 4.5E-14 0.009 0.001 3.9E-13 0.007 0.003 3.1E-02 
na DRD2 rs7121986 11:113355444 T 0.37 -0.008 0.001 6.2E-14 -0.008 0.001 1.3E-13 -0.005 0.003 1.1E-01 
na DPP6 rs6969458 7:153489725 A 0.47 0.008 0.001 6.4E-14 0.008 0.001 1.3E-12 0.007 0.003 1.5E-02 
RP11-308N19.1 ZNF462 rs74424378 9:109331094 T 0.76 0.009 0.001 1.7E-13 0.009 0.001 4.5E-13 0.006 0.003 8.4E-02 
ARHGAP15, AC096558.1, RP11-
570L15.2 ARHGAP15 rs13024996 2:144225215 A 0.37 -0.008 0.001 4.4E-13 -0.008 0.001 6.6E-13 -0.004 0.003 1.4E-01 
MLXIPL MLXIPL rs34060476 7:73037956 A 0.87 -0.011 0.002 5.0E-13 -0.012 0.002 1.4E-13 -0.004 0.004 4.1E-01 
na FAM178A rs61873510 10:102626510 T 0.33 -0.008 0.001 5.1E-13 -0.008 0.001 9.8E-12 -0.008 0.003 1.7E-02 
FTO FTO rs1421085 16:53800954 T 0.60 0.008 0.001 9.2E-13 0.007 0.001 1.7E-10 0.010 0.003 9.2E-04 
na PMFBP1 rs11648570 16:72356964 T 0.89 -0.012 0.002 2.1E-12 -0.011 0.002 1.5E-10 -0.013 0.005 3.4E-03 
OTX2, RP11-1085N6.6 OTX2 rs2277499 14:57271127 T 0.34 -0.008 0.001 2.2E-12 -0.007 0.001 2.4E-09 -0.012 0.003 9.1E-05 
PDE4B PDE4B rs2310752 1:66392405 A 0.43 -0.007 0.001 2.8E-12 -0.008 0.001 1.8E-11 -0.006 0.003 4.2E-02 
SERPINA1 SERPINA1 rs112635299 14:94838142 T 0.02 -0.025 0.004 3.7E-12 -0.027 0.004 9.8E-12 -0.017 0.010 9.9E-02 
na AJAP1 rs780569 1:4569436 A 0.71 -0.008 0.001 5.2E-12 -0.008 0.001 1.1E-11 -0.005 0.003 1.2E-01 
na VRK2 rs10496076 2:57942987 T 0.37 -0.007 0.001 9.7E-12 -0.007 0.001 1.3E-09 -0.009 0.003 1.6E-03 
ACTR10, C14orf37 ACTR10 rs71414193 14:58685301 A 0.19 -0.009 0.001 1.8E-11 -0.008 0.001 5.8E-09 -0.013 0.004 4.5E-04 
BEND4 BEND4 rs16854020 4:42117559 A 0.13 0.010 0.002 2.9E-11 0.010 0.002 5.8E-09 0.016 0.005 6.4E-04 
na SORL1 rs485425 11:121544984 C 0.45 -0.007 0.001 6.1E-11 -0.007 0.001 7.3E-11 -0.004 0.003 1.9E-01 
SEZ6L2 SEZ6L2 rs113443718 16:29892184 A 0.31 -0.007 0.001 7.4E-11 -0.008 0.001 4.5E-11 -0.003 0.003 2.9E-01 
CBX5, RP11-968A15.2 CBX5 rs57281063 12:54660427 A 0.41 0.007 0.001 7.9E-11 0.007 0.001 1.8E-09 0.007 0.003 1.2E-02 
na TNRC6A rs72768626 16:24693048 A 0.94 0.014 0.002 9.7E-11 0.015 0.002 1.7E-09 0.014 0.006 1.8E-02 
SYT14 SYT14 rs227179 1:210216731 A 0.59 -0.007 0.001 1.1E-10 -0.007 0.001 1.4E-09 -0.006 0.003 2.8E-02 
TCF4 TCF4 rs9320010 18:53053897 A 0.60 0.007 0.001 1.1E-10 0.007 0.001 1.6E-09 0.007 0.003 2.2E-02 
SBK1 NPIPB6 rs2726034 16:28336882 T 0.68 0.007 0.001 1.4E-10 0.007 0.001 1.1E-09 0.006 0.003 4.7E-02 
ANKRD36 ANKRD36 rs13390019 2:97797680 T 0.87 0.010 0.002 1.6E-10 0.011 0.002 7.0E-11 0.004 0.005 4.5E-01 
na ELAVL4 rs7517344 1:50711961 A 0.17 0.009 0.001 1.9E-10 0.008 0.001 2.5E-07 0.016 0.004 2.1E-05 
LINC00461 MEF2C rs4916723 5:87854395 A 0.58 0.007 0.001 2.1E-10 0.007 0.001 5.1E-10 0.005 0.003 1.1E-01 
ARPC1B, ARPC1A ARPC1B rs10249167 7:98980879 A 0.87 0.010 0.002 2.9E-10 0.009 0.002 8.1E-08 0.015 0.004 3.8E-04 
EFNB3, WRAP53 EFNB3 rs7640 17:7606722 C 0.80 0.008 0.001 4.3E-10 0.009 0.001 1.3E-09 0.006 0.004 9.9E-02 
RP11-501C14.5 IGF2BP1 rs4794015 17:47067826 A 0.41 0.007 0.001 4.3E-10 0.006 0.001 5.4E-08 0.009 0.003 1.2E-03 
TCAP, PNMT, STARD3 TCAP rs1053651 17:37822311 A 0.27 -0.007 0.001 1.1E-09 -0.008 0.001 8.4E-10 -0.003 0.003 2.8E-01 
na AADAT rs7698119 4:171070910 A 0.49 -0.006 0.001 1.3E-09 -0.006 0.001 1.6E-07 -0.009 0.003 1.6E-03 
STAT6, AC023237.1 STAT6 rs12312693 12:57511734 T 0.55 -0.006 0.001 1.5E-09 -0.006 0.001 9.5E-09 -0.005 0.003 5.6E-02 
SCN8A SCN8A rs7958704 12:51984349 T 0.41 -0.006 0.001 1.6E-09 -0.006 0.001 1.7E-08 -0.006 0.003 3.5E-02 
ACSS3 ACSS3 rs11114787 12:81595700 T 0.27 0.007 0.001 2.0E-09 0.007 0.001 2.7E-08 0.007 0.003 2.4E-02 
RP11-32K4.1 BHLHE22 rs2356369 8:64956882 T 0.52 -0.006 0.001 2.0E-09 -0.006 0.001 4.1E-08 -0.007 0.003 1.6E-02 
ZRANB2-AS2 ZRANB2 rs12031875 1:71585097 A 0.82 -0.008 0.001 2.2E-09 -0.008 0.001 7.6E-08 -0.010 0.004 8.7E-03 
MSANTD1, HTT MSANTD1 rs12646808 4:3249828 T 0.66 0.007 0.001 2.4E-09 0.007 0.001 1.1E-09 0.002 0.003 4.7E-01 
TENM2 TENM2 rs10078588 5:166816176 A 0.52 0.006 0.001 2.5E-09 0.006 0.001 4.3E-08 0.007 0.003 1.9E-02 
IGSF9B IGSF9B rs748919 11:133783232 T 0.79 0.008 0.001 3.3E-09 0.008 0.001 1.0E-08 0.005 0.003 1.1E-01 
AC010967.2 GPR75-ASB3 rs785293 2:53023304 A 0.57 -0.006 0.001 3.3E-09 -0.006 0.001 3.2E-08 -0.006 0.003 3.8E-02 
BDNF, RP11-587D21.4 BDNF rs988748 11:27724745 C 0.21 -0.008 0.001 4.4E-09 -0.007 0.001 1.2E-07 -0.010 0.004 8.3E-03 
SNP: Single Nucleotide polymorphism; LocusName: Nearest Gene; rsID_LEAD_SNP: Rs ID number of the lead SNP;  CP: Chromosome/Position (build hg19/37); EA: Effect allele of 
the discovered SNP; EAF: Frequency of the effect allele; BETA_comb: Effect size in meta-analysis; SE_comb; Standard Error of the effect in meta-analysis; P_comb: Meta-analysis 
P-value; BETA_UKB: Effect size in UK Biobank analysis; SE_UKB: Standard Error of the effect in the UK Biobank analysis; P_UKB: UK Biobank analysis P-
value;BETA_AlcGenCHARGE+: Effect size in the AlcGen meta-analysis; SE_AlcGenCHARGE+: Standard Error of the effect in the AlcGen meta-analysis; P_AlcGenCHARGE+: AlcGen 
meta-analysis P-value 
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FIGURE CAPTIONS 1200 
Figure 1. Manhattan plot showing P-values from discovery genome-wide 1201 
association meta-analysis with alcohol intake (log g/d) among 480,842 individuals 1202 
across UK Biobank, AlcGen and CHARGE+, excluding known variants. The P-value 1203 
was computed using inverse variance fixed effects models. The y axis shows the –1204 
log10 P values and the x axis shows their chromosomal positions. Horizontal blue line 1205 
represents the threshold of P = 5 x 10-9. 1206 
 1207 
Figure 2. Association of alcohol intake loci with other traits. Plot shows results from 1208 
associations with other traits which were extracted from the PhenoScanner database 1209 
for the 46 novel sentinel SNPs including proxies in Linkage Disequilibrium (r2 ≥ 0.8) 1210 
with genome-wide significant associations. Each colored line connects a specific 1211 
variant with the associated traits and diseases. 1212 
 1213 
Figure 3. Mediation effect of the grey matter volume of  bilateral putamen on the 1214 
relationship between SNP rs13107325 and alcohol intake. The green is for left 1215 
putamen, and, the red is for the right one.  We use ‘a’ for the relationship between 1216 
rs13107325 and putamen, ‘b’ for the relationship between putamen and alcohol 1217 
consumption, ‘c’ for the relationship between rs13107325 and alcohol consumption, 1218 
‘c’’ for the relationship between rs13107325 and alcohol consumption after 1219 
excluding the effect of putamen, and ‘ab’ as the mediation effect. The significance 1220 
tests are based on the bootstrapping method (10,000 times). Z- statistics and the 1221 
corresponding P values are provided in parentheses. The brain icon was created 1222 
using Mango software, version 4.1 (http://ric.uthscsa.edu/mango/). 1223 
 1224 
Figure 4. Comparison of Zip8 alcohol phenotypes in Drosophila. Flies were exposed 1225 
to 100/50 Ethanol/Air vapor for 30 min for exposure 1, and the time to 50% loss of 1226 
righting was determined (ST-50, sedation time).  After recovery on food for 4 hours, 1227 
flies were re-exposed to the same vapors, and the second ST-50 recorded (left side).  1228 
The resulting increase in ST-50, i.e. tolerance, is shown on the right. In a) 1229 
overexpressed human hZIP8 in ics-expressing cells flies are compared against 1230 
controls whereas in b) knockdown of the fly ortholog dZip71B is compared against 1231 
controls. In c) flies carrying two transposon insertions in the endogenous dZip71B 1232 
gene are compared against controls. Significance levels: ***P <0.001, **P <0.01, *P 1233 
<0.05. Exact P-values are presented in the text.  1234 
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